This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Tiagabine (TGB) is a γ-aminobutyric acid (GABA) reuptake inhibitor approved as adjunctive therapy for partial seizures in patients over age 12. It has been used off-label to treat depression, anxiety, bipolar disorder, neuropathic pain, headache, and spasticity. A recent epidemiologic study found that TGB adjunctive therapy does not increase the risk of status epilepticus (SE).1 However, there are now more than a dozen reports of precipitation of nonconvulsive status epilepticus (NCSE) in patients predisposed to seizures, including children,2 or in patients without epilepsy treated chronically with TGB.3 In February 2005, Cephalon, the manufacturer of TGB, issued a warning of the possibility of seizures in patients without epilepsy.
We report a case of NCSE after TGB overdose in a 14-year-old girl who neither had epilepsy nor was taking the medication chronically. The present description clarifies some inaccuracies in an earlier report by others of our clinical and EEG findings in this case.4
Case report.
The patient was a 14-year-old right-handed girl in good health except for mild asthma. On the day of admission, she was found at home obtunded after having ingested an estimated …
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Hastening the Diagnosis of Amyotrophic Lateral Sclerosis
Dr. Brian Callaghan and Dr. Kellen Quigg